Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?The Motley Fool • 07/30/26
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/27/26
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 07/24/26
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool • 07/22/26
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 07/17/26
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader MarketZacks Investment Research • 07/16/26
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key FactsZacks Investment Research • 07/10/26
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR TherapeuticsThe Motley Fool • 07/08/26
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?The Motley Fool • 07/07/26
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/06/26
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 06/27/26
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 06/26/26
CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to NoteZacks Investment Research • 06/17/26
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key FactsZacks Investment Research • 06/11/26